A systematic review of cannabidiol dosing in clinical populations

This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical ...

Conclusion. This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as ...

A systematic review of cannabidiol dosing in clinical populations

Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied ...

Cannabidiol (CBD): A Systematic Review of Clinical and ... - MDPI

Conclusions: Although clinical and preclinical research show promising results, clinical evidence is limited, and more studies should be performed in the future ...

A Systematic Review of Medical Cannabinoids Dosing in Human

Positive effects were reported in clinical studies: 52% with THC (range, 0.01–0.5 mg/kg/d [0.62–31 mg/d]), 74% with CBD (range, 1–50 mg/kg/d [62–3100 mg/d]), 64 ...

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults

The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was ...

A systematic review of cannabidiol dosing in clinical populations

AimsCannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in ...

The safety and efficacy of low oral doses of cannabidiol: An ...

At present, there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10–50 mg/kg) in treating intractable ...

Cannabinoid treatments for anxiety: A systematic review and ...

However, its efficacy in healthy and clinical populations, treatment duration, formulation and doses for optimal therapeutic benefits remains unclear. Selected ...

A Systematic Review on the Pharmacokinetics of Cannabidiol in ...

Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published ...

Safety of low dose cannabidiol

systematic review of cannabidiol dosing in clinical populations. British journal of clinical pharmacology, 85(9), pp.1888-1900. 6 Shannon, S. and Opila ...

Cannabinoids for Medical Use: A Systematic Review and Meta ...

The trial reported that cannabidiol was associated with a greater improvement on the anxiety factor of a visual analogue mood scale (mean ...

Efficacy and safety of medical cannabinoids in children - Nature

While cannabidiol was associated with a reduction in reported seizure events (RR = 0.59, 95% CI [0.36–0.97]), no association was found in ...

Safety of CBD in Humans – A Literature Review (As of December 12 ...

Thus, data on long-term exposure to oral CBD in healthy and at-risk populations are lacking. • Clinical trials of repeated doses in patients have provided, ...

A Systematic Review of Medical Cannabinoids Dosing in Human

Inclusion criteria were articles that assessed administration of any cannabinoid to any clinical population, reported in the. ClinicalTrials.gov or PubMed ...

Randomized, dose-ranging safety trial of cannabidiol in Dravet ...

CBD oral solution (GW Pharmaceuticals Ltd., London, UK) contained 25 or 100 mg/mL CBD; placebo was identical except for the absence of CBD. Study medication was ...

Review of cannabidiol: Report of the Science Advisory Committee ...

The committee recommends that packaging for health products containing CBD should have clear dosing instructions and warnings of potential side ...

Medicinal cannabis for psychiatric disorders: a clinically-focused ...

The systematic review of the literature was conducted during 2019, assessing the data from all case studies and clinical trials involving ...

Cannabidiol for moderate–severe insomnia: a randomized ...

A recent review investigated the efficacy of CBD with various doses taken during a single dosing session or longer periods of up to 6 months of ...

210365Orig1s000 - accessdata.fda.gov

... dosing regimen appropriate for the general patient population ... At the end of the review cycle, the applicant submitted the CSR of the clinical DDI study ...